Drug-induced suppression of phosphorylase kinase activity correlates with resolution of psoriasis as assessed by clinical, histological and immunohistochemical parameters - PubMed (original) (raw)
Clinical Trial
Drug-induced suppression of phosphorylase kinase activity correlates with resolution of psoriasis as assessed by clinical, histological and immunohistochemical parameters
M C Heng et al. Br J Dermatol. 2000 Nov.
Abstract
Background: Phosphorylase kinase (PhK), also known as adenosine triphosphate (ATP)-phosphorylase b phosphotransferase, integrates multiple calcium/calmodulin-dependent signalling pathways, including those involved in cell migration and cell proliferation, while coupling these pathways to glycogenolysis and ATP-dependent phosphorylation, thus ensuring continuing energy supply for these activities.
Objectives: Our laboratory recently reported correlation of elevated PhK activity with psoriatic activity. This study further evaluates the significance of drug-induced suppression of PhK activity on psoriatic activity.
Patients and methods: PhK activity was assayed in four groups, each with 10 patients: (i) active untreated psoriasis; (ii) resolving psoriasis treated by calcipotriol (Dovonex(R), Bristol Myers Squibb, Princeton, NJ, U.S.A. ), a vitamin D3 analogue and an indirect inhibitor of PhK; (iii) curcumin (diferuloylmethane), a selective PhK inhibitor; and (iv) 10 normal non-psoriatic subjects.
Results: PhK activity in units mg-1 protein was highest in active untreated psoriasis (1204 +/- 804.3; mean +/- SD), lower in the calcipotriol-treated group (550.7 +/- 192. 9), lower in curcumin-treated group (207.2 +/- 97.6), and lowest in normal skin (105.4 +/- 44.6). One-way analysis of variance performed on log-transformed PhK activity measure showed significant differences among the four groups, F3,36 = 48.79, P < 0.0001. Decreased PhK activity in curcumin-and calcipotriol-treated psoriasis was associated with corresponding decreases in keratinocyte transferrin receptor (TRR) expression, severity of parakeratosis and density of epidermal CD8+ T cells.
Conclusions: Our results demonstrate that drug-induced suppression of PhK activity is associated with resolution of psoriatic activity as assessed by clinical, histological and immunohistochemical criteria, and support the hypothesis that effective antipsoriatic activity may be achieved through modulation of PhK activity.
Similar articles
- Biologic effects of topical calcipotriol (MC 903) treatment in psoriatic skin.
Reichrath J, Müller SM, Kerber A, Baum HP, Bahmer FA. Reichrath J, et al. J Am Acad Dermatol. 1997 Jan;36(1):19-28. doi: 10.1016/s0190-9622(97)70320-7. J Am Acad Dermatol. 1997. PMID: 8996256 - The effects of calcipotriol and methylprednisolone aseponate on bcl-2, p53 and ki-67 expression in psoriasis.
Adişen E, Gülekon A, Erdem O, Dursun A, Gürer MA. Adişen E, et al. J Eur Acad Dermatol Venereol. 2006 May;20(5):527-33. doi: 10.1111/j.1468-3083.2006.01508.x. J Eur Acad Dermatol Venereol. 2006. PMID: 16684279 Clinical Trial. - Decrease in enkephalin levels in psoriatic lesions after calcipotriol and mometasone furoate treatment.
Nissen JB, Avrach WW, Hansen ES, Stengaard-Pedersen K, Kragballe K. Nissen JB, et al. Dermatology. 1999;198(1):11-7. doi: 10.1159/000018057. Dermatology. 1999. PMID: 10026395 Clinical Trial. - Signaling pathways targeted by curcumin in acute and chronic injury: burns and photo-damaged skin.
Heng MC. Heng MC. Int J Dermatol. 2013 May;52(5):531-43. doi: 10.1111/j.1365-4632.2012.05703.x. Epub 2012 Dec 11. Int J Dermatol. 2013. PMID: 23231506 Review. - Calcipotriol. A new topical antipsoriatic.
Kragballe K, Iversen L. Kragballe K, et al. Dermatol Clin. 1993 Jan;11(1):137-41. Dermatol Clin. 1993. PMID: 8435908 Review.
Cited by
- Curcumin: A Contact Allergen.
Chaudhari SP, Tam AY, Barr JA. Chaudhari SP, et al. J Clin Aesthet Dermatol. 2015 Nov;8(11):43-8. J Clin Aesthet Dermatol. 2015. PMID: 26705440 Free PMC article. - Suppression of experimental choroidal neovascularization by curcumin in mice.
Xie P, Zhang W, Yuan S, Chen Z, Yang Q, Yuan D, Wang F, Liu Q. Xie P, et al. PLoS One. 2012;7(12):e53329. doi: 10.1371/journal.pone.0053329. Epub 2012 Dec 28. PLoS One. 2012. PMID: 23285282 Free PMC article. - "Spicing up" of the immune system by curcumin.
Jagetia GC, Aggarwal BB. Jagetia GC, et al. J Clin Immunol. 2007 Jan;27(1):19-35. doi: 10.1007/s10875-006-9066-7. Epub 2007 Jan 9. J Clin Immunol. 2007. PMID: 17211725 Review. - Amelioration of renal ischaemia-reperfusion injury by liposomal delivery of curcumin to renal tubular epithelial and antigen-presenting cells.
Rogers NM, Stephenson MD, Kitching AR, Horowitz JD, Coates PT. Rogers NM, et al. Br J Pharmacol. 2012 May;166(1):194-209. doi: 10.1111/j.1476-5381.2011.01590.x. Br J Pharmacol. 2012. PMID: 21745189 Free PMC article. - Efficacy and safety of curcumin in psoriasis: preclinical and clinical evidence and possible mechanisms.
Zhang S, Wang J, Liu L, Sun X, Zhou Y, Chen S, Lu Y, Cai X, Hu M, Yan G, Miao X, Li X. Zhang S, et al. Front Pharmacol. 2022 Aug 29;13:903160. doi: 10.3389/fphar.2022.903160. eCollection 2022. Front Pharmacol. 2022. PMID: 36120325 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous